Daiichi Sankyo (OTCMKTS:DSNKY) Rating Lowered to “Strong Sell” at Zacks Research

Posted by Dante Gardener on Aug 5th, 2026

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Monday,Zacks.com reports.

Separately, Jefferies Financial Group lowered shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce”.

Read Our Latest Stock Analysis on DSNKY

Daiichi Sankyo Stock Down 3.0%

DSNKY opened at $16.00 on Monday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.64 and a current ratio of 2.42. The stock has a fifty day moving average of $16.49 and a 200-day moving average of $17.61. Daiichi Sankyo has a fifty-two week low of $14.98 and a fifty-two week high of $27.50. The company has a market capitalization of $29.81 billion, a P/E ratio of 18.60, a P/E/G ratio of 2.89 and a beta of -0.18.

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo had a return on equity of 14.22% and a net margin of 10.92%.Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, equities analysts expect that Daiichi Sankyo will post 0.96 EPS for the current year.

Daiichi Sankyo Company Profile

(Get Free Report)

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.